1Pitt B, Zannad F, Remme WJ, et al. For the randomized Aldactone Evaluation Study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 1999,341:709 - 711
2Delyani JA. Anti-aldosterone therapy in the treatment of heart failure new thoughts on an old hormone. Exp Qpin Invest Drugs, 1998,7:753- 759
3Duprez DA, Bauwens FR, De Buyzere ML, et al.Influence of blood pressure and aldosterone on left ventriculasr hypertrophy in moderate essential hypertention. Am J Cardiol, 1993,71:17A - 20A
4Swedberg K, Eneroth P, Kjekshus J, et al. For the CONSENUS Trail Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation,1999,82:1730 - 1736
5Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironalactone in preventing myocardial fibrosis in systemic arterial hypertention. Am J Cardiol, 1993,71:12A - 16A
6Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium:fibrosis and renin-angiotensin-aldosterone system. Circulation, 1991,83:1849- 1865
7Brunner HR, Laragg JH, Newton MA, et al. Essential hypertention: rennin and aldosterone, heart attack and stroke. N Engl J Med, 1972,286:441 -449
